Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2017; 17(5):339-342
DOI: 10.5428/pcar20170506
Pharmaceutical care for the patient with diabetic foot infection complicated with hepatic and renal dysfunctions
1. WU Hui1(1.Department of Pharmacy,First People’s Hospital of Yancheng,Jiangsu Province,Jiangsu Yancheng 224001,China wuhui0922@hotmail.com)
2. 2( 2.Department of Clinic Pharmacy,First People’s Hospital Affiliated to Shanghai Jiaotong University,Shanghai 200080,China )
3. SHI WeiFeng2(2.Department of Clinic Pharmacy,First People’s Hospital Affiliated to Shanghai Jiaotong University,Shanghai 200080,China sypharmacy@126.com)
ABSTRACT  Objective: To investigate methods and modes of standard pharmaceutical care for the patients with type 2 diabetes complicated with hepatic and renal dysfunctions. Methods: Through active involvement in the treatment process of 1 case of type 2 diabetes complicated with hepatic and renal dysfunctions,clinical pharmacists offered good advice on the administration of anti-diabetic drugs,anti-bacterial and anti-hepatitis B virus drugs,and above all provided individualized pharmaceutical care. Results: Through integrated pharmaceutical care,clinical pharmacists duly found out and solved related problems concerning drug treatment,thus promoting rational medication clinically. Conclusion: Integration of clinical pharmacists into the medical care team and active pharmaceutical care could contribute to the promotion of rational medication clinically.
Welcome to PCAR! You are the number 95 reader of this article!
Please cite this article as:
WU Hui1,2,SHI WeiFeng2,. Pharmaceutical care for the patient with diabetic foot infection complicated with hepatic and renal dysfunctions[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2017; 17(5): 339-342.
References:
1. American Diabetes Association. Standards of medical care in diabetes-2016[J].Diabetes Care,2016,39(6):e88-e89.
2. McGuire H,Longson D,Adler A,et al. Management of type 2 diabetes in adults: summary of updated NICE guidance[J]. BMJ,2016,353:i1575.
3. Josse R G,Chiasson J L,Ryan E A,et al.Acarbose in the treatment of elderly patients with type 2 diabetes[J]. Diabetes Res Clin Pract,2003,59:37-42.
4. MU YiMing,JI LiNong,NING Guang, et al. Chinese experts consensus statement on metformin in clinical practice[J].Chin J Diabetes,2014,22(8):673-681. In Chinese with English title.
5. Wukich D K,Armstrong D G,Attinger C E,et al. Inpatient management of diabetic foot disorders: a clinical guide[J]. Diabetes Care,2013,36(9):2862-2871.
6. Zubair M,Malik A,Ahmad J. Clinico-microbiological study and antimicrobial drug resistance profile of diabetic foot infections in North India[J].Foot (Edinb),2011,21(1):6-14.
7. LIU YaJun,HOU JianHong,YUAN MingYuan. Distribution of pathogenic bacteria causing diabetic foot infections[J]. Chin J Nosocomiol,2014,24(4):833-834,840. In Chinese with English abstract.
8. CHEN XiongWei,ZHENG LiuJuan,LI WeiJia,et al. Pathogenic bacteria causing infections in diabetic foot patients[J]. Chin J Nosocomiol,2014,24(1):76-77,80. In Chinese with English abstract.
9. WANG Wei,YUE Yan,HAO LiLi,et al. Clinical effect of probiotics on the treatment of antibiotic-associated diarrhea[J]. Chin J Nosocomiol,2016,26(6):1258-1260. In Chinese with English abstract.
10. Hempel S,Newberry S J,Maher A R,et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis[J]. JAMA,2012,307(18):1959-1969.
11. Kogan M. Probiotics and antibiotic-associated diarrhoea[J]. Lancet,2014,383(9911):29-30.
12. HU JianFang,SHAO Qin,WANG ZhaoHan,et al.Corelation between intra-abdominal pressure and plasma aldosterone in cirrhotic patients with ascites[J]. Chin J Clinicians(Elect ed),2015,9(12):2314-2317. In Chinese with English abstract.
13. Runyon B A. Introduction to the revised American Association for the study of liver diseases practice guideline management of adult patients with ascites due to cirrhosis 2012[J]. Hepatology,2013,57(4):1651-1653.
14. DENG HouLiang,YIN JinJin,ZHANG JingJing,et al. Meta-analysis of methylcobalamin alone and in combination with prostaglandin E1 in the treatment of diabetic peripheral neuropathy[J]. Endocrine,2014,46(3):445-454.
15. JIANG DeQi,LI MingXing,Wang Yan,et al. Effects of prostaglandin E1 plus methylcobalamin alone and in combination with lipoic acid on nerve conduction velocity in patients with diabetic peripheral neuropathy: a meta-analysis[J].Neurosci Lett,2015,594:23-29.
16. Hotta N,Kawamori R,Fukuda M,et al. Long-term clinical effects of epalrestat,an aldose reductase inhibitor,on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy[J].Diabet Med,2012,29(12):1529-1533.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口